← Back to headlines
JPMorgan Reiterates Rating on Ionis Pharmaceuticals Based on Dosing Advantage
JPMorgan maintained its existing investment rating on Ionis Pharmaceuticals, citing the company's dosing regimen advantages and positive outlook for its therapeutic pipeline.
31 Aug, 07:32 — 31 Aug, 07:32
Sources
Showing 1 of 1 sources
